Stryker Corporation (SYK) fair value analysis
S&P 500 · Updated 2026-10-19
SYK price how computed
Forward Fair Value verdict
UndervaluedSYK is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $277.33
- Sector
- Healthcare
- 12-month range
- $269.75–$387.46
- Market cap
- $106B
- From 52-week high
- -28.4%
- Shares outstanding
- 384M
- Rank in Healthcare by discount to fair value
- #12 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Stryker Corporation is a medical technology company that manufactures and sells orthopedic implants, surgical instruments, medical devices, and software systems used in operating rooms and patient care settings. The company operates globally, serving hospitals, surgical centers, and healthcare providers across North America, Europe, Asia-Pacific, and other international markets.
SYK currently ranks #12 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $106B
- P/E (trailing)
- 20x
- Revenue (TTM)
- $25.8B
- Net margin
- 14.4%
- EPS (TTM)
- $13.95
- Gross margin
- 68.3%
- Debt / equity
- 0.62
- Revenue growth (3-yr avg)
- 11.4%
- Shares outstanding
- 384M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
- DCF cross-check
- Overvalued
Technicals how computed
- RSI (14-day)
- 65 · neutral
- 50-day average
- $299.95
- 200-day average
- $326.64
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Dividends how computed
- Paid, last 12 months
- $3.52 per share (4 payments)
- Yield on last price
- 1.27%
- Consecutive years of increases
- 16
- Last ex-dividend date
- 2026-09-30
- Last payment date
- 2026-10-30
Earnings how computed
- Next earnings report
- 2026-10-29 (post-market)
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+6.6%)
2026-03 ▼ miss (-12.8%)
2025-12 ▲ beat (+1.6%)
2025-09 ▲ beat (+1.9%)
2025-06 ▲ beat (+2.0%)
2025-03 ▲ beat (+4.0%)
2024-12 ▲ beat (+3.6%)
2024-09 ▲ beat (+3.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 22 buy · 6 hold · 0 sell (28 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $363
- Target vs last price
- +30.9%
What our data shows for SYK
- Our model validated 17 trailing price-to-earnings windows for SYK, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $269.75–$387.46.
- The 14-day relative strength index sits at a neutral 65.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for SYK
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent SYK news
TickrTrends' derived news-sentiment signal for SYK is currently leaning positive, computed from recent coverage.
- Stryker: Q2 Recovery And Portfolio Expansion Strengthen The Operating Story (NYSE:SYK) (seekingalpha.com, 2026-10-13)
TickrTrends take: Stryker's Q2 recovery and portfolio expansion efforts suggest the company is strengthening its operational foundation during a period when TickrTrends currently rates it as undervalued. A valuation-focused investor should monitor whether these operational improvements translate into margin expansion and whether the portfolio additions generate sufficient revenue growth to justify the company's current healthcare sector positioning. The combination of recovery momentum and strategic expansion activity provides context for evaluating whether the current undervalued designation reflects genuine opportunity or requires reassessment as operational results materialize. - Stryker (SYK) Invests $400M in CMR Surgical to Boost Versius Robotics Line (gurufocus.com, 2026-10-12)
TickrTrends take: Stryker's 400 million dollar investment in CMR Surgical signals confidence in the Versius robotic surgery platform as a competitive offering in the high-growth surgical robotics market. Given TickrTrends' undervalued assessment, this capital deployment demonstrates management's commitment to expanding its surgical technology portfolio, which could strengthen the company's competitive positioning against established robotics competitors. Valuation-focused readers should monitor whether this investment translates into meaningful revenue contributions and market share gains in surgical robotics, as successful execution could support a re-rating of the stock from its current undervalued status. - Stryker (SYK) Is Changing CEOs After the Stock Fell 25% Over Twelve Months (insidermonkey.com, 2026-10-09)
TickrTrends take: Stryker's leadership transition occurs against a backdrop of significant shareholder losses, which may prompt investors to evaluate whether recent operational challenges are reflected in the company's current market price. TickrTrends currently assesses SYK as undervalued within the Healthcare sector, suggesting that the market may have overcorrected on the stock's recent performance. A change in executive leadership could represent a potential catalyst for operational improvements, making the valuation assessment relevant for investors monitoring whether the new direction leads to fundamental performance recovery.
What people are saying
Follow the SYK conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — # SYK - Weekly Indicator Summary TickrTrends' derived indicators for Stryker Corporation show a shift in momentum this week, with the RSI zone moving from oversold conditions into neutral territory. The current valuation verdict remains undervalued for the healthcare sector company. This transition suggests a reduction in the intensity of selling pressure compared to the previous week.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is SYK stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), SYK is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is SYK's TickrTrends verdict?
SYK's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does SYK compare to other Healthcare stocks?
SYK ranks #12 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is SYK overbought or oversold?
SYK's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does SYK pay a dividend?
Yes. SYK paid $3.52 per share over the last twelve months (4 payments), a 1.27% yield on TickrTrends' last price, and has raised the annual total for 16 consecutive years. The last ex-dividend date was 2026-09-30.
When does SYK report earnings next?
SYK's next earnings report is scheduled for 2026-10-29 (post-market), per the published earnings calendar.
Does SYK usually beat earnings estimates?
Over its last 8 reported quarters SYK beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about SYK?
Of 28 analysts covering SYK, 22 rate it a buy, 6 a hold and 0 a sell - buy-leaning, with a consensus price target of $363 (+30.9% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
SYK vs ANIP · SYK vs AXGN · SYK vs COO · SYK vs DXCM · SYK vs EMBC